Related Experiment Videos
Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma
G Bellone1, A Carbone, D Tibaudi
1Department of Clinical Physiopathology, University of Torino, Via Genova, 3, 10126, Turin, Italy. graziella.bellone@unito.it
Abstract:
Transforming growth factor (TGF)-beta is a protein family which affects multiple cellular functions including survival, proliferation, differentiation and adhesion. Among the three known isoforms, TGF-beta1 is commonly overexpressed in solid malignancies. Recent studies in knock-out mice demonstrated non-redundant roles of different TGF-beta isoforms in development. The present study was performed to assess tumour-associated expression of the three TGF-beta isoforms in colon carcinoma. We report that colon carcinoma progression is associated with gradual and significant increases in expression of TGF-beta1 and TGF-beta2 mRNA and proteins. By contrast, TGF-beta3 expression was detected in normal colonic mucosa and, at slightly higher levels, in tumour tissues. In addition, plasma levels of both TGF-beta1 and TGF-beta2 were significantly higher in cancer patients when compared with unaffected individuals. Taken together, our results indicate distinct expression patterns of the three TGF-beta isoforms in colon carcinoma cells and possible systemic effects of TGF-beta1 and TGF-beta2 in tumour patients.
Insights
Transforming growth factor-beta (TGF-beta) isoforms show distinct expression patterns in colon cancer. TGF-beta1 and TGF-beta2 increase with tumor progression, suggesting roles in cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Transforming growth factor-beta (TGF-beta) is a protein family regulating crucial cellular functions.
- TGF-beta1 is frequently overexpressed in various solid tumors.
- Distinct roles of TGF-beta isoforms in development are increasingly recognized.
Purpose of the Study:
- To investigate the expression patterns of the three TGF-beta isoforms (TGF-beta1, TGF-beta2, TGF-beta3) in colon carcinoma.
- To correlate TGF-beta isoform expression with colon cancer progression.
- To assess potential systemic alterations in TGF-beta levels in cancer patients.
Main Methods:
- Quantitative analysis of TGF-beta1, TGF-beta2, and TGF-beta3 mRNA and protein expression in colon carcinoma tissues.
- Comparison of TGF-beta isoform expression in tumor tissues versus normal colonic mucosa.
- Measurement of plasma levels of TGF-beta1 and TGF-beta2 in colon cancer patients and healthy controls.
Main Results:
- Colon carcinoma progression is linked to significant increases in TGF-beta1 and TGF-beta2 mRNA and protein levels.
- TGF-beta3 expression is present in normal colonic mucosa and slightly elevated in tumors.
- Elevated plasma levels of TGF-beta1 and TGF-beta2 are observed in colon cancer patients compared to controls.
Conclusions:
- The three TGF-beta isoforms exhibit distinct expression profiles in colon carcinoma.
- TGF-beta1 and TGF-beta2 expression increases with tumor progression and may have systemic implications.
- These findings highlight the complex role of TGF-beta signaling in colon cancer pathogenesis.